Wan Tai Biotechnology: Application for the market approval of varicella live attenuated vaccine has been accepted.

Wan Tai Biology announced that its wholly-owned subsidiary, Beijing Wan Tai Biological Pharmaceutical Co., Ltd., recently received the "Acceptance Notice" for the application for the market approval of the varicella attenuated live vaccine issued by the Drug Evaluation Center of the National Medical Products Administration. The drug name is varicella attenuated live vaccine, the dosage form is injection, and the specification is 0.5ml per bottle after reconstitution. The dose for human use is 0.5ml each time, containing not less than 3.3lgPFU of varicella-zoster virus. It will take a relatively long period from the acceptance of the market approval application for the varicella attenuated live vaccine to its approval and listing, and it will not have a significant impact on the company's financial condition and operating performance in the short term.